We’re pleased to share that Pluristyx, a BroadOak Capital Partners portfolio company, has recently completed an investment round to expand inventory with new clinical grade cell lines. This strategic investment will enable Pluristyx to be the industry leader offering the highest quality stem cells available anywhere.
The full press release is below.
Seattle, Washington: July 28, 2025 – Pluristyx, a leading provider of induced pluripotent stem cell (iPSC) technologies and proprietary gene editing solutions, today announced the successful close of its most recent round of funding led by BioLife Solutions, the global leader in cryopreservation technologies and systems that support cell and gene therapy (CGT) manufacturing, and BroadOak Capital Partners, a specialist investor in the life science tools and services industry.
The newly raised capital will enable Pluristyx to expand inventory with new clinical grade cell lines incorporating Pluristyx’s proprietary FailSafe® and iACT™ engineering and hypoimmune genetic edits in its best-in-class, polyclonal, synthetic RNA reprogramed iPSCs. These proprietary cells are specifically designed to support making next-generation genetically engineered, stem cell-derived therapies and support uniquely safe, effective, and scalable living medicines. The funding will also support Pluristyx’s recently launched PluriForm™ kit, which provides researchers with streamlined tools for generating organoids and other complex test systems.
“We are incredibly excited for the successful close of this round and gratified to have industry leaders and peers validate our vision with their investment,” said Benjamin Fryer, PhD, CEO of Pluristyx. “The support from our Seattle area neighbor, BioLife Solutions, and continued support from our colleagues at BroadOak Partners will allow us to manufacture, commercialize, and distribute our innovative solutions and help our customers solve critical industry challenges.”
Roderick de Greef, BioLife’s Chairman and CEO, remarked, “We have known and worked with the founding team at Pluristyx for many years, and have a great deal of respect for their scientific expertise in cell therapy. Their recent development of an iPSC-based biological assay for organoid manufacturing dovetails with our interest in exploring biological assays more broadly as a product portfolio adjacency.”
“We are excited to continue our support of Dr. Fryer and the entire Pluristyx team”, said Daniel Friedman, Principal at BroadOak Capital Partners. “Pluristyx is differentiated by its suite of proprietary technologies that directly address some of the most critical scientific challenges of the iPSC field.”
iPSCs are unique tools and building blocks for medicines. In addition to applications for innovative new toxicology, safety, and efficacy assays to replace animal models, Pluristyx’s products are the ideal universal raw material to produce living medicines to cure currently untreatable diseases. This strategic investment will enable Pluristyx to be the industry leader offering the highest quality stem cells available anywhere.
Stay connected
Partner with BroadOak